KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Tax Provisions (2018 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Tax Provisions for 8 consecutive years, with $538000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 113.98% to $538000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 124.85% year-over-year, with the annual reading at $1.0 million for FY2025, 124.85% up from the prior year.
  • Tax Provisions for Q4 2025 was $538000.0 at Xenon Pharmaceuticals, down from $677000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $1.2 million in Q4 2022, with the low at -$3.8 million in Q4 2024.
  • Average Tax Provisions over 5 years is -$160450.0, with a median of -$181000.0 recorded in 2021.
  • Peak annual rise in Tax Provisions hit 3557.14% in 2021, while the deepest fall reached 6700.0% in 2021.
  • Over 5 years, Tax Provisions stood at $484000.0 in 2021, then skyrocketed by 144.42% to $1.2 million in 2022, then tumbled by 117.33% to -$205000.0 in 2023, then plummeted by 1777.07% to -$3.8 million in 2024, then surged by 113.98% to $538000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $538000.0, $677000.0, and -$626000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.